EMA accepts Cubist Pharma antibiotic MAA

|By:, SA News Editor

The European Medicines Agency accepts Cubist Pharmaceuticals' (NASDAQ:CBST) Marketing Authorization Application for ceftolozane/tazobactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections. The European Commission should announce its decision by 2H 2015.